Abstract
Abstract There is an urgent need for unbiased evaluations of potential therapeutic treatments. An early indicator of treatment efficacy might allow for a more individualized and effective therapeutic regimen. In the present study we employed the MNU model of ER+ mammary tumors to address this question. Rats were treated with MNU at 50 days of age. When an animal developed a palpable mammary tumor it was randomized either to Iressa (6 mg/kg BW) or vehicle. Two days following this time animals were biopsied. Three days later animals were replaced on Iressa or vehicle for a period of 6 weeks. The objective was to determine whether tumors that responded to Iressa over a 6 week period exhibited changes in collagen fibril orientation relative to unresponsive tumors within two days of initial treatment. We examined collagen fibril orientation at the tumor-stromal interface. We employed a second harmonic generation (SHG) imaging protocol and examined collagen fiber orientation in normal glands, untreated tumors, tumors treated for 2 days which would then regress or not. We found that untreated tumors or non responsive tumors appeared to have a relatively disoriented pattern at the tumor-stromal interface whereas responding tumors within two days of treatment showed greater orientation of collagen fibrils oriented parallel to the tumor boundary. Thus the degree or extent of radially-aligned collagen fibrils in the tumor-stromal interface of rodent mammary tumor tissue is an indicator of chemotherapeutic potential of the EGFr inhibitor, Gefitinib (Iressa). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 441. doi:10.1158/1538-7445.AM2011-441
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
